Found: 25
Select item for more details and to access through your institution.
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
- Published in:
- Diabetologia, 2016, v. 59, n. 4, p. 700, doi. 10.1007/s00125-015-3845-8
- By:
- Publication type:
- Article
A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 674, doi. 10.1111/dom.14260
- By:
- Publication type:
- Article
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/ mL in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 1032, doi. 10.1111/dom.12938
- By:
- Publication type:
- Article
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 5, p. 622, doi. 10.1111/dom.12856
- By:
- Publication type:
- Article
Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 2, p. 208, doi. 10.1111/dom.12803
- By:
- Publication type:
- Article
Euglycaemic glucose clamp: what it can and cannot do, and how to do it.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 10, p. 962, doi. 10.1111/dom.12703
- By:
- Publication type:
- Article
Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro.
- Published in:
- Diabetes Care, 2005, v. 28, n. 10, p. 2400, doi. 10.2337/diacare.28.10.2400
- By:
- Publication type:
- Article
Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Absorption and Metabolic Effect of Inhaled Insulin.
- Published in:
- Diabetes Care, 2002, v. 25, n. 12, p. 2276, doi. 10.2337/diacare.25.12.2276
- By:
- Publication type:
- Article
Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 9, p. 885, doi. 10.1007/s40261-017-0539-7
- By:
- Publication type:
- Article
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 5, p. 503, doi. 10.1007/s40261-017-0499-y
- By:
- Publication type:
- Article
Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region.
- Published in:
- Clinical Drug Investigation, 2014, v. 34, n. 9, p. 673, doi. 10.1007/s40261-014-0218-x
- By:
- Publication type:
- Article
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 5, p. 497, doi. 10.1002/jcph.443
- By:
- Publication type:
- Article
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action 每日1次给予德谷胰岛素(一种持续作用时间超长的基础胰岛素)治疗后在2-3日内可以达到稳态
- Published in:
- Journal of Diabetes, 2016, v. 8, n. 1, p. 132, doi. 10.1111/1753-0407.12266
- By:
- Publication type:
- Article
Continuous Glucose Monitoring Before and After Exercise in Patients with Type 1 Diabetes on CSH.
- Published in:
- Diabetes, 2007, v. 56, p. A108
- By:
- Publication type:
- Article
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study.
- Published in:
- Clinical Pharmacokinetics, 2020, v. 59, n. 12, p. 1601, doi. 10.1007/s40262-020-00901-2
- By:
- Publication type:
- Article
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 1, p. 255, doi. 10.1007/s13300-014-0070-2
- By:
- Publication type:
- Article
Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion.
- Published in:
- Diabetes Care, 2009, v. 32, n. 8, p. 1437, doi. 10.2337/dc09-0595
- By:
- Publication type:
- Article
Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy.
- Published in:
- Diabetes Care, 2009, v. 32, n. 8, p. 1431, doi. 10.2337/dc09-0097
- By:
- Publication type:
- Article
Dose-Response Relationship of Insulin Glulisine in Subjects With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2007, v. 30, n. 10, p. 2506, doi. 10.2337/dc06-2114
- By:
- Publication type:
- Article
130-LB: Comparative PK and PD of the Rapid-Acting Insulin Aspart Product SAR341402, NovoLog, and NovoRapid in Subjects with T1D.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-130-LB
- By:
- Publication type:
- Article
1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1100-P
- By:
- Publication type:
- Article